SHORT TERM EFFECTS OF ROSUVASTATIN ON PLASMA CONCENTRATION OF HIGH SENSITIVITY C-REACTIVE PROTEIN IN PATIENTS WITH CHRONIC STABLE ANGINA
DOI:
https://doi.org/10.47144/phj.v45i1.134Keywords:
hs-CRP, chronic stable angina, rosuvastatin, lipid profileAbstract
Objective: To determine the short term effects of rosuvastatin on elevated baseline high-sensitivity C-reactive protein (hs-CRP) in patients with chronic stable
angina.
Methodology: This Quasi-experimental comparative study was conducted in
Cardiology department, Lady Reading Hospital Peshawar, between March 2010
and February, 2011. We selected 44 consecutive patients age 40 years or above,
of any gender having hs-CRP levels ≥1.2mg/l with chronic stable angina. Base
line levels of hs-CRP, total cholesterol, LDL cholesterol, HDL cholesterol,
triglycerides, and creatine phosphokinase (CPK) were measured in fasting
status. These patients were treated with rosuvastatin 20 mg once daily at night
and followed up for one month. Using SPSS version 16 data was analyzed.
Results: Mean age was 53±7.2 and 50% were females. Following treatment with
rosuvastatin 20mg for one month the mean hs-CRP levels reduced from
4.08±2.56 to 2.72±2.40 (95%CI, 0.41 to 2.29, p=0.006). Similarly mean total
cholesterol levels decreased from 185.88±37.62 to 147.45±38.35,
(p=0.0001). LDL cholesterol decreased from 118.34±31.31 to 86.63±35.72
(p= 0.0001). But mean HDL cholesterol had no significant increase from
baseline levels i.e. from 32.18±9.93 to 33.95±7.65 (p=0.174). TGs levels
reduced from 240.11±123.66 to 197.43±88.24 (p=0.008). Mean CPK levels
did not differ significantly from base line at follow up, from 101.43±58.63 to
96.22±55.10 (p=0.646).
Conclusion: Short term treatment with rosuvastatin significantly decreases
elevated hs-CRP levels in patients with chronic stable angina.
Downloads
Downloads
How to Cite
Issue
Section
License
When an article is accepted for publication in the print format, the author will be required to transfer exclusive copyright to the PHJ and retain the rights to use and share their published article with others. However, re-submission of the full article or any part for publication by a third party would require prior permission of the PHJ.
Online publication will allow the author to retain the copyright and share the article under the agreement described in the licensing rights with creative commons, with appropriate attribution to PHJ. Creative Commons attribution license CC BY 4.0 is applied to articles published in PHJ https://creativecommons.org/licenses/by/4.0/